<p>SOPHiA GENETICS SA（纳斯达克代码：SOPH - 获取免费报告）在十月份经历了显著的空头头寸下降。截至 10 月 15 日，空头头寸总计 21,800 股，较 9 月 30 日的 33,200 股下降了 34.3%。根据 87,500 股的平均日交易量，当前的空头头寸比率为 0.2 天。目前，公司 0.0% 的股份被卖空。目前，公司 0.0% 的股份被卖空。根据 87,500 股的平均日交易量，当前的空头头寸比率为 0.2 天。</p>
<p>获取 <strong>SOPHiA GENETICS</strong> 警报：</p>
<h2>对 SOPHiA GENETICS 的对冲基金看法</h2>
<p>一些机构投资者最近买入和卖出了 SOPH 的股票。瑞银资产管理公司（UBS AM）作为瑞银资产管理美洲的一个独立业务单位，在第一季度将其在 SOPHiA GENETICS 的持股增加了 246.9%。瑞银资产管理公司现在拥有 7,632,871 股公司股票，价值 25,341,000 美元，在此期间又购买了 5,432,871 股。Akre Capital Management LLC 在第二季度将其在 SOPHiA GENETICS 的持股增加了 66.2%。Akre Capital Management LLC 现在拥有 3,719,140 股公司股票，价值 11,529,000 美元，在上个季度又购买了 1,481,636 股。Archon Capital Management LLC 在第二季度购买了 SOPHiA GENETICS 的新头寸，价值约 997,000 美元。Ensign Peak Advisors Inc 在第二季度购买了 SOPHiA GENETICS 的新头寸，价值约 775,000 美元。最后，Rathbones Group PLC 在第二季度购买了 SOPHiA GENETICS 的新股份，价值约 504,000 美元。31.59% 的股票由机构投资者持有。</p>
<h2>华尔街分析师看法</h2>
<p>几家券商最近对 SOPH 发布了报告。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 SOPHiA GENETICS 股票的 “卖出（d-）” 评级。Wall Street Zen 在星期六将 SOPHiA GENETICS 的评级上调至 “持有”。一位股票研究分析师对该股票给予了买入评级，另一位则给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 8.00 美元。</p>
<p><strong>查看我们关于 SOPH 的最新报告</strong></p>
<h2>SOPHiA GENETICS 股票表现</h2>
<p>SOPH 的股票在星期五下跌了 0.19 美元，达到 5.00 美元。该公司的股票交易量为 157,207 股，而其平均交易量为 139,344 股。该股票的 50 日简单移动平均为 3.89 美元，200 日简单移动平均为 3.41 美元。该公司的债务与股本比率为 0.62，流动比率为 3.39，速动比率为 3.21。该股票的市值为 3.379 亿美元，市盈率为-11.36，贝塔值为 1.10。SOPHiA GENETICS 的 12 个月低点为 2.58 美元，12 个月高点为 5.30 美元。</p>
<p>SOPHiA GENETICS（纳斯达克代码：SOPH - 获取免费报告）最近在 8 月 5 日星期二发布了季度财报。该公司报告季度每股收益为 0.33 美元，超出共识预期的-0.25 美元，超出幅度为 0.58 美元。该业务在本季度的收入为 1832 万美元，而共识预期为 1749 万美元。SOPHiA GENETICS 的净利润率为-40.99%，股本回报率为-30.69%。SOPHiA GENETICS 已设定 2025 财年的每股收益指引。研究分析师预测 SOPHiA GENETICS 在当前财年将发布-0.96 美元的每股收益。</p>
<h2>SOPHiA GENETICS 公司简介</h2>
<p>（获取免费报告）</p>
<p>SOPHiA GENETICS SA 作为一家云原生软件技术公司在医疗保健领域运营。该公司提供 SOPHiA DDM 平台，这是一个用于分析数据和从多模态数据集及诊断方式中生成洞察的云原生软件平台。其 SOPHiA DDM 平台及相关解决方案、应用、产品和服务通过其自有销售团队以及在瑞士、法国、意大利、欧洲其他地区、北美、美国、拉丁美洲和亚太地区的分销商和行业合作伙伴提供给医院、实验室和生物制药公司。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 SOPHiA GENETICS</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>Lemonade 股票在财报后是否会迎来大幅反弹？</li>
<li>3 只可以帮助抵御通货膨胀的食品杂货股票</li>
<li>Caterpillar 股票可能在年底前超过 650 美元</li>
<li>3 只值得长期持有的 REITs</li>
<li>ServiceNow 的 5 比 1 拆股是投资者买入的信号</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 SOPHiA GENETICS 吗？</h2>
<p>在考虑 SOPHiA GENETICS 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 SOPHiA GENETICS 并不在名单上。</p>
<p>虽然 SOPHiA GENETICS 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SOPH

<p>SOPHiA GENETICS SA (NASDAQ:SOPH) 在十月份的空头头寸下降了 34.3%，截至 10 月 15 日，共有 21,800 股被卖空。覆盖天数比率为 0.2 天，表明空头卖出活动较低。机构投资者持有该股票的 31.59%，瑞银资产管理显著增加了其持股比例。分析师的评级意见不一，普遍评级为 “持有”，目标价为 8.00 美元。该股票目前交易价格为 5.00 美元，市值为 3.379 亿美金，市盈率为-11.36。公司在上个季度报告的收益好于预期</p>

<p>SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 21,800 shares, a decline of 34.3% from the September 30th total of 33,200 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days.</p>
<div class="lb-trans"><p>SOPHiA GENETICS SA（纳斯达克代码：SOPH - 获取免费报告）在十月份经历了显著的空头头寸下降。截至 10 月 15 日，空头头寸总计 21,800 股，较 9 月 30 日的 33,200 股下降了 34.3%。根据 87,500 股的平均日交易量，当前的空头头寸比率为 0.2 天。目前，公司 0.0% 的股份被卖空。目前，公司 0.0% 的股份被卖空。根据 87,500 股的平均日交易量，当前的空头头寸比率为 0.2 天。</p>
</div><p>Get <strong>SOPHiA GENETICS</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>SOPHiA GENETICS</strong> 警报：</p>
</div><h2>Hedge Funds Weigh In On SOPHiA GENETICS</h2>
<div class="lb-trans"><h2>对 SOPHiA GENETICS 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Archon Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at about $997,000. Ensign Peak Advisors Inc bought a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at approximately $775,000. Finally, Rathbones Group PLC purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $504,000. 31.59% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了 SOPH 的股票。瑞银资产管理公司（UBS AM）作为瑞银资产管理美洲的一个独立业务单位，在第一季度将其在 SOPHiA GENETICS 的持股增加了 246.9%。瑞银资产管理公司现在拥有 7,632,871 股公司股票，价值 25,341,000 美元，在此期间又购买了 5,432,871 股。Akre Capital Management LLC 在第二季度将其在 SOPHiA GENETICS 的持股增加了 66.2%。Akre Capital Management LLC 现在拥有 3,719,140 股公司股票，价值 11,529,000 美元，在上个季度又购买了 1,481,636 股。Archon Capital Management LLC 在第二季度购买了 SOPHiA GENETICS 的新头寸，价值约 997,000 美元。Ensign Peak Advisors Inc 在第二季度购买了 SOPHiA GENETICS 的新头寸，价值约 775,000 美元。最后，Rathbones Group PLC 在第二季度购买了 SOPHiA GENETICS 的新股份，价值约 504,000 美元。31.59% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师看法</h2>
</div><p>Several brokerages recently issued reports on SOPH. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Wall Street Zen raised SOPHiA GENETICS to a &#34;hold&#34; rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>几家券商最近对 SOPH 发布了报告。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 SOPHiA GENETICS 股票的 “卖出（d-）” 评级。Wall Street Zen 在星期六将 SOPHiA GENETICS 的评级上调至 “持有”。一位股票研究分析师对该股票给予了买入评级，另一位则给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 8.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on SOPH</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SOPH 的最新报告</strong></p>
</div><h2>SOPHiA GENETICS Stock Performance</h2>
<div class="lb-trans"><h2>SOPHiA GENETICS 股票表现</h2>
</div><p>Shares of SOPH traded down $0.19 on Friday, reaching $5.00. The company's stock had a trading volume of 157,207 shares, compared to its average volume of 139,344. The stock's 50 day simple moving average is $3.89 and its two-hundred day simple moving average is $3.41. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 3.21. The stock has a market capitalization of $337.90 million, a P/E ratio of -11.36 and a beta of 1.10. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $5.30.</p>
<div class="lb-trans"><p>SOPH 的股票在星期五下跌了 0.19 美元，达到 5.00 美元。该公司的股票交易量为 157,207 股，而其平均交易量为 139,344 股。该股票的 50 日简单移动平均为 3.89 美元，200 日简单移动平均为 3.41 美元。该公司的债务与股本比率为 0.62，流动比率为 3.39，速动比率为 3.21。该股票的市值为 3.379 亿美元，市盈率为-11.36，贝塔值为 1.10。SOPHiA GENETICS 的 12 个月低点为 2.58 美元，12 个月高点为 5.30 美元。</p>
</div><p>SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.58. The business had revenue of $18.32 million for the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. Research analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>SOPHiA GENETICS（纳斯达克代码：SOPH - 获取免费报告）最近在 8 月 5 日星期二发布了季度财报。该公司报告季度每股收益为 0.33 美元，超出共识预期的-0.25 美元，超出幅度为 0.58 美元。该业务在本季度的收入为 1832 万美元，而共识预期为 1749 万美元。SOPHiA GENETICS 的净利润率为-40.99%，股本回报率为-30.69%。SOPHiA GENETICS 已设定 2025 财年的每股收益指引。研究分析师预测 SOPHiA GENETICS 在当前财年将发布-0.96 美元的每股收益。</p>
</div><h2>SOPHiA GENETICS Company Profile</h2>
<div class="lb-trans"><h2>SOPHiA GENETICS 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.</p>
<div class="lb-trans"><p>SOPHiA GENETICS SA 作为一家云原生软件技术公司在医疗保健领域运营。该公司提供 SOPHiA DDM 平台，这是一个用于分析数据和从多模态数据集及诊断方式中生成洞察的云原生软件平台。其 SOPHiA DDM 平台及相关解决方案、应用、产品和服务通过其自有销售团队以及在瑞士、法国、意大利、欧洲其他地区、北美、美国、拉丁美洲和亚太地区的分销商和行业合作伙伴提供给医院、实验室和生物制药公司。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than SOPHiA GENETICS</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Is Lemonade Stock Set for a Big Squeeze After Earnings?</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Caterpillar Stock Could Top $650 by Year’s End</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>ServiceNow’s 5-for-1 Split Is a Signal for Investors to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 SOPHiA GENETICS</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>Lemonade 股票在财报后是否会迎来大幅反弹？</li>
<li>3 只可以帮助抵御通货膨胀的食品杂货股票</li>
<li>Caterpillar 股票可能在年底前超过 650 美元</li>
<li>3 只值得长期持有的 REITs</li>
<li>ServiceNow 的 5 比 1 拆股是投资者买入的信号</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in SOPHiA GENETICS Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 SOPHiA GENETICS 吗？</h2>
</div><p>Before you consider SOPHiA GENETICS, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 SOPHiA GENETICS 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前买入……而 SOPHiA GENETICS 并不在名单上。</p>
</div><p>While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 SOPHiA GENETICS 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

SOPHiA GENETICS SA（NASDAQ 代码：SOPH）空头头寸更新